Medicines labeled for the same conditions
Alternatives to abatacept
8 other medicines are given the same way (subcutaneous) and in the same FDA class as abatacept or labeled mainly for the same use (rheumatoid arthritis); the others include 4 tumor necrosis factor blockers, 2 interleukin-6 receptor antagonists and 1 folate analog metabolic inhibitor (FDA labels read October 8, 2026).
Which medicines are labeled for the same conditions as abatacept?
Rheumatoid arthritis lists all 46 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (subcutaneous) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Abataceptselective t cell costimulation modulator | this medicine | none listed | $1,469.23 per mL 125 mg/mL syringe | No | No current entry |
| Adalimumabtumor necrosis factor blocker | Rheumatoid arthritis | none listed | $1,587.82 per mL 40 mg/0.4 mL | Yes | No current entry |
| Methotrexatefolate analog metabolic inhibitor | Rheumatoid arthritis | none listed | $289.37 per mL 25 mg/0.5 mL autoinj | Yes | In shortage |
| Tocilizumabinterleukin-6 receptor antagonist | Rheumatoid arthritis | none listed | $821.00 per mL 162 mg/0.9 mL autoinjct | Yes | No current entry |
| Etanercepttumor necrosis factor blocker | Rheumatoid arthritis | none listed | $2,084.14 per mL 25 mg/0.5 mL syringe | Yes | No current entry |
| Sarilumabinterleukin-6 receptor antagonist | Rheumatoid arthritis | none listed | $2,075.30 per mL 200 mg/1.14 mL pen injection | Yes | No current entry |
| Certolizumabtumor necrosis factor blocker | Rheumatoid arthritis | none listed | $6,094.02 per syringe 2x200 mg/mL syringe kit | Yes | No current entry |
| Golimumabtumor necrosis factor blocker | Rheumatoid arthritis | none listed | $12,890.32 per mL 50 mg/0.5 mL pen injec | Yes | No current entry |
| Adalimumab-aacf | Rheumatoid arthritis | none listed | n/a | Yes | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What do pharmacies pay for each?
The headline NADAC price per unit of each medicine's most widely listed form; strengths differ, so compare like with like on each record.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What next?
- Abatacept: the full record
- label, generics, price, shortages, recalls
- Abatacept vs certolizumab
- two records side by side